Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00927498 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title 
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old (NCT00927498)

Trial Description
The main objective of this study is to compare conventional chemotherapy: daunorubicin (DaunoXome®; Gilead Sciences Inc.) and the azacitidine (Vidaza®; Celgene Co.) and this chemotherapy in combination with the monoclonal antibody-drug conjugate used gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in divided doses.

This trial is sponsored by Acute Leukemia French Association (ALFA) [1]

Study Data

Study Schematic

Click here to Return to Drug map


Last Editorial review: September 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar